Log in

Relevant bibliographies by topics / Anticancer treatment / Journal articles

To see the other types of publications on this topic, follow the link: Anticancer treatment.

Journal articles on the topic 'Anticancer treatment'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anticancer treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Frączek, Paulina, Aneta Kilian-Kita, Mirosława Püsküllüoglu, and Krzysztof Krzemieniecki. "Acupuncture as anticancer treatment?" Współczesna Onkologia 6 (2016): 453–57. http://dx.doi.org/10.5114/wo.2016.65604.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

de Bree, Eelco, John Romanos, and Dimitris D. Tsiftsis. "Hyperthermia in anticancer treatment." European Journal of Surgical Oncology (EJSO) 28, no. 1 (February 2002): 95. http://dx.doi.org/10.1053/ejso.2001.1220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Falanga, Anna, and Marina Marchetti. "Anticancer treatment and thrombosis." Thrombosis Research 129, no. 3 (March 2012): 353–59. http://dx.doi.org/10.1016/j.thromres.2011.10.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Attina, Giorgio, Stefano Mastrangelo, and Antonio Ruggiero. "Telomerase and Anticancer Treatment." Biomedical and Pharmacology Journal 15, no. 4 (December 20, 2022): 1881–88. http://dx.doi.org/10.13005/bpj/2526.

Full text

Abstract:

Current chemotherapy uses compounds of organometallic nature that act with different mechanisms of action. Many pharmacological studies are directed toward the creation of compounds with more specific and selective activity toward tumor targets, including telomerase. The design and synthesis of such compounds with specific antitelomerase activity must consider the mechanism of action of the enzyme and its structure. The discovery of a close correlation between telomerase activation, cell immortalization and oncogenesis has suggested that telomerase inhibitors could be potent therapeutic agents, capable of selectively killing cancer cells. Inhibition of telomerase is expected to lead toward shortening of telomeres to a critical length, such that replicative senescence and cell death due to irreparable chromosomal damage can result. It has been observed that cancer cells generally have shorter telomeres than the normal replicative cell population, probably because the malignant cells have undergone more divisions. Therefore, the inhibition telomeres of cancer cells after a few cycles of cell division, without the normal cells suffering harmful consequences during therapy. Telomerase is certainly an interesting target on which to continue to study molecules that inhibit its function to obtain a specificity of therapeutic intervention and a reduction of the nonspecific cytotoxicity of chemotherapy.

APA, Harvard, Vancouver, ISO, and other styles

5

Combrink, Margaretha Johanna W., and Johanna Elizabeth Maree. "The Transition From Palliation With Anticancer Treatment to Palliation Without Anticancer Treatment." Journal of Hospice & Palliative Nursing 18, no. 5 (October 2016): 421–28. http://dx.doi.org/10.1097/njh.0000000000000267.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ayyad, Rezk R., Ahmed M. Mansour, Ahmed M. Nejm, Yasser Abdel Allem Hassan, and Ahmed R. Ayyad. "An Overview of Antibiotics Used in Cancer Treatment and Drugs that Act as Antimicrotubules." Journal of Progress in Engineering and Physical Science 3, no. 2 (June 2024): 25–32. http://dx.doi.org/10.56397/jpeps.2024.06.04.

Full text

Abstract:

The caner in general is an abnormal growth with no causes and route of transportation in the body, which is the difficult of treatment or limited of its spread. One of the methods of treatment is the chemotherapeutic agents, we will overview on Antibiotics and Antimicrotubules act as Anticancer. The Anticancer Antibiotics are Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Plicamycin, Doxorubicin, Mitomycin. Antimicrotubules, mostly, they are naturally compounds which inhibit the microtubules which responsible for the cell division and proliferation of the cancer cell specifically as Colchicine, Vincristine, Vinblastine, hence the Antibiotic Anticancers and Antimicrotubules are important to know its importance in cancer treatment.

APA, Harvard, Vancouver, ISO, and other styles

7

Tiwari, Deepanshi, and Mamta Tiwari. "Vincristine: Beyond on anticancer treatment." International Journal of Pharmacognosy and Life Science 1, no. 2 (July 1, 2020): 38–43. http://dx.doi.org/10.33545/27072827.2020.v1.i2a.17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Timing of anticancer treatment crucial." Inpharma Weekly &NA;, no. 870 (January 1993): 4. http://dx.doi.org/10.2165/00128413-199308700-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Nozières, C., C. Damatte-Fauchery, and F. Borson-Chazot. "Thyroid effects and anticancer treatment." Annales d'Endocrinologie 72, no. 3 (June 2011): 198–202. http://dx.doi.org/10.1016/j.ando.2011.04.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Pelicano, H., D. S. Martin, R.-H. Xu, and P. Huang. "Glycolysis inhibition for anticancer treatment." Oncogene 25, no. 34 (August 2006): 4633–46. http://dx.doi.org/10.1038/sj.onc.1209597.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Dąbrowska, Krystyna, Zuzanna Kaźmierczak, Joanna Majewska, Paulina Miernikiewicz, Agnieszka Piotrowicz, Joanna Wietrzyk, Dorota Lecion, et al. "Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment." Future Microbiology 9, no. 7 (July 2014): 861–69. http://dx.doi.org/10.2217/fmb.14.50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Palmieri, Vittorio, Maria Teresa Vietri, Andrea Montalto, Andrea Montisci, Francesco Donatelli, Enrico Coscioni, and Claudio Napoli. "Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs." Cancers 15, no. 8 (April 10, 2023): 2224. http://dx.doi.org/10.3390/cancers15082224.

Full text

Abstract:

Background: Anticancer treatments are improving the prognosis of patients fighting cancer. However, anticancer treatments may also increase the cardiovascular (CV) risk by increasing metabolic disorders. Atherosclerosis and atherothrombosis related to anticancer treatments may lead to ischemic heart disease (IHD), while direct cardiac toxicity may induce non-ischemic heart disease. Moreover, valvular heart disease (VHD), aortic syndromes (AoS), and advanced heart failure (HF) associated with CV risk factors and preclinical CV disease as well as with chronic inflammation and endothelial dysfunction may also occur in survivors of anti-carcer treatments. Methods: Public electronic libraries have been searched systematically looking at cardiotoxicity, cardioprotection, CV risk and disease, and prognosis after cardiac surgery in survivors of anticancer treatments. Results: CV risk factors and disease may not be infrequent among survivors of anticancer treatments. As cardiotoxicity of established anticancer treatments has been investigated and is frequently irreversible, cardiotoxicity associated with novel treatments appears to be more frequently reversible, but also potentially synergic. Small reports suggest that drugs preventing HF in the general population may be effective also among survivors of anticancer treatments, so that CV risk factors and disease, and chronic inflammation, may lead to indication to cardiac surgery in survivors of anticancer treatments. There is a lack of substantial data on whether current risk scores are efficient to predict prognosis after cardiac surgery in survivors of anticancer treatments, and to guide tailored decision-making. IHD is the most common condition requiring cardiac surgery among survivors of anticancer treatments. Primary VHD is mostly related to a history of radiation therapy. No specific reports exist on AoS in survivors of anticancer treatments. Conclusions: It is unclear whether interventions to dominate cancer- and anticancer treatment-related metabolic syndromes, chronic inflammation, and endothelial dysfunction, leading to IHD, nonIHD, VHD, HF, and AoS, are as effective in survivors of anticancer treatments as in the general population. When CV diseases require cardiac surgery, survivors of anticancer treatments may be a population at specifically elevated risk, rather than affected by a specific risk factor.

APA, Harvard, Vancouver, ISO, and other styles

13

Shahab, Ariba, and Subuhi Anwar. "CRUCUMIN ROLE IN BREAST CANCER TREATMENT." Era's Journal of Medical Research 10, no. 01 (June 2023): 97–103. http://dx.doi.org/10.24041/ejmr2023.16.

Full text

Abstract:

One of the most common forms of malignant tumors is breast cancer worldwide, has a high fatality rate. The development of novel chemicals and technological advancements that will allow the adoption of safer and more efficient therapeutic techniques has received a lot of attention in order to address this problem. In order to maximize tumor growth inhibition and reduce side effects, it has been suggested that combining nanoparticles with well-known anticancer agents including compounds derived from plants, like curcumin is an effective strategy. Curcumin exploits a complex network of molecular signals, including the proliferative, ER, and HER2 pathways, to exert its anticancer actions. According to experimental results, curcumin controls genes associated to cell phase, microRNA, and apoptosis in breast cancer cells.

APA, Harvard, Vancouver, ISO, and other styles

14

Tripathi, Nishita, Daniya Sheikh, and Demetra Antimisiaris. "Anticancer Therapy in COVID-19 Patients: A Descriptive Literature Review." Senior Care Pharmacist 36, no. 8 (August 1, 2021): 365–74. http://dx.doi.org/10.4140/tcp.n.2021.365.

Full text

Abstract:

Objective: To provide a descriptive literature review about the effects of anticancer treatment on clinical outcomes because of active COVID-19 infection in older people. Data Sources: A literature search was conducted in Google Scholar, PubMed, American Society of Clinical Oncology, European Society for Medical Oncology, and the Center for Disease Control and Prevention. Articles published in English between December 1, 2019, to September 1, 2020, were included. Study Selection: Nine studies assessing the effectiveness of various modalities for cancer treatments in patients infected with COVID-19 infection were reviewed. The studies reviewed the severity of COVID-19 infection outcomes in patients who underwent any anticancer treatment. Studies exclusively focused on older people could not be found, but all studies included older people. Data Synthesis and Results: Early pandemic studies suggested avoiding anticancer treatment during a COVID-19 infection because of poor clinical outcomes and increased mortality. However, the totality of studies reviewed found no association between the continuation of anticancer treatment and adverse COVID-19 outcomes in cancer patients. Adverse COVID-19 infection outcomes and high mortality rates were associated with older cancer patients independent of anticancer therapy. Conclusion: Treatment of cancer could be challenging because of the COVID-19 pandemic. Interruption or delaying the anticancer therapy could increase the burden of overall mortality. This literature review indicated that adverse outcomes because of COVID-19 are associated with advanced age independent of anticancer therapy. Further exploration of the correlation between cancer, anticancer treatments, and COVID-19 infection outcomes is needed.

APA, Harvard, Vancouver, ISO, and other styles

15

Magné, Nicolas, Cécile Pacaut, and Cyrus Chargari. "21st International Congress on Anticancer Treatment." Expert Review of Anticancer Therapy 10, no. 5 (May 2010): 647–49. http://dx.doi.org/10.1586/era.10.39.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

TUCKER, MIRIAM E. "Metformin Investigated as Possible Anticancer Treatment." Internal Medicine News 42, no. 19 (November 2009): 22. http://dx.doi.org/10.1016/s1097-8690(09)70777-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Stoff, Jesse A. "Selected Office Based Anticancer Treatment Strategies." Journal of Oncology 2019 (January 15, 2019): 1–14. http://dx.doi.org/10.1155/2019/7462513.

Full text

Abstract:

Over the years, the treatment of patients with cancer has varied widely as much because of recent advancements in science and medicine as the philosophies that belie their use. This paper briefly describes many of the prevailing approaches in use today with an attempt to offer some perspective of how to apply these disparate methodologies so that they may be more effectively integrated, resulting in consistently better clinical responses.

APA, Harvard, Vancouver, ISO, and other styles

18

Berghmans, T. "Hyponatremia related to medical anticancer treatment." Supportive Care in Cancer 4, no. 5 (September 1996): 341–50. http://dx.doi.org/10.1007/bf01788840.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Huang, Huanshao, Jiajun Wang, Junai Zhang, Jiye Cai, Jiang Pi, and Jun-Fa Xu. "Inspirations of Cobalt Oxide Nanoparticle Based Anticancer Therapeutics." Pharmaceutics 13, no. 10 (October 2, 2021): 1599. http://dx.doi.org/10.3390/pharmaceutics13101599.

Full text

Abstract:

Cobalt is essential to the metabolism of all animals due to its key role in cobalamin, also known as vitamin B12, the primary biological reservoir of cobalt as an ultra-trace element. Current cancer treatment strategies, including chemotherapy and radiotherapy, have been seriously restricted by their side effects and low efficiency for a long time, which urges us to develop new technologies for more effective and much safer anticancer therapies. Novel nanotechnologies, based on different kinds of functional nanomaterials, have been proved to act as effective and promising strategies for anticancer treatment. Based on the important biological roles of cobalt, cobalt oxide nanoparticles (NPs) have been widely developed for their attractive biomedical applications, especially their potential for anticancer treatments due to their selective inhibition of cancer cells. Thus, more and more attention has been attracted to the preparation, characterization and anticancer investigation of cobalt oxide nanoparticles in recent years, which is expected to introduce novel anticancer treatment strategies. In this review, we summarize the synthesis methods of cobalt oxide nanoparticles to discuss the advantages and restrictions for their preparation. Moreover, we emphatically discuss the anticancer functions of cobalt oxide nanoparticles as well as their underlying mechanisms to promote the development of cobalt oxide nanoparticles for anticancer treatments, which might finally benefit the current anticancer therapeutics based on functional cobalt oxide nanoparticles.

APA, Harvard, Vancouver, ISO, and other styles

20

Usuwanthim, Kanchana, Prapakorn Wisitpongpun, and Thitiya Luetragoon. "Molecular Identification of Phytochemical for Anticancer Treatment." Anti-Cancer Agents in Medicinal Chemistry 20, no. 6 (June 14, 2020): 651–66. http://dx.doi.org/10.2174/1871520620666200213110016.

Full text

Abstract:

Cancer commands the second highest global mortality rate and causes severe public health problems. Recent advances have been made in cancer therapy but the incidence of the disease remains high. Research on more efficient treatment methods with reduced side effects is necessary. Historically, edible plants have been used as traditional medicines for various diseases. These demonstrate the potential of natural products as sources of bioactive compounds for anticancer treatment. Anticancer properties of phytochemicals are attributed to bioactive compounds in plant extracts that suppress cancer cell proliferation and growth by inducing both cell cycle arrest and apoptosis. This review presents a summary of the molecular identification of phytochemicals with anticancer properties and details their action mechanisms and molecular targets. Moreover, the effects of the natural product on both immunomodulatory and anticancer properties are provided.

APA, Harvard, Vancouver, ISO, and other styles

21

Ying, Hua-Zhong, Chen-Huan Yu, Hao-Kun Chen, Huan-Huan Zhang, Jie Fang, Fang Wu, and Wen-Ying Yu. "Quinonoids: Therapeutic Potential for Lung Cancer Treatment." BioMed Research International 2020 (April 7, 2020): 1–13. http://dx.doi.org/10.1155/2020/2460565.

Full text

Abstract:

Lung cancer is the leading cause of cancer-related deaths worldwide. Owing to its high incidence and mortality, the development and discovery of novel anticancer drugs is of great importance. In recent years, many breakthroughs have been achieved in the search for effective anticancer substances from natural products. Many anticancer drugs used clinically and proven to be effective are derived from natural products. Quinonoids, including naphthoquinones, phenanthrenequinones, benzoquinones, and anthraquinones, constitute a large group of natural bioactive compounds that widely exist in higher and lower plant species. Given that most of these compounds possess anticancer effects, they are applied in many cancer studies, especially in lung cancer research. They can promote apoptosis, induce autophagy, and inhibit proliferation, angiogenesis, and cell invasion and migration. Some drugs can enhance anticancer effects when combined with other drugs. Thus, quinonoids have broad application prospects in the treatment of lung cancer. Here, we summarize the previous studies on the antilung cancer activities of quinonoids together with their underlying mechanisms and analyze the common research targets with different effects so as to provide references for the discovery of quinonoids against lung cancer.

APA, Harvard, Vancouver, ISO, and other styles

22

Połubok, Joanna, Aleksandra Gonera, Olimpia Jasielska, Dorota Sęga-Pondel, Karolina Galant, Bernarda Kazanowska, and Ewa Barg. "Evaluation of selected endocrine disorders after anticancer treatment of solid tumors in childhood." Pediatric Endocrinology Diabetes and Metabolism 21, no. 2 (2015): 56–64. http://dx.doi.org/10.18544/pedm-21.02.0025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Villéger, Romain, Amélie Lopès, Guillaume Carrier, Julie Veziant, Elisabeth Billard, Nicolas Barnich, Johan Gagnière, Emilie Vazeille, and Mathilde Bonnet. "Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?" International Journal of Molecular Sciences 20, no. 18 (September 17, 2019): 4584. http://dx.doi.org/10.3390/ijms20184584.

Full text

Abstract:

Recently, preclinical and clinical studies targeting several types of cancer strongly supported the key role of the gut microbiota in the modulation of host response to anti-tumoral therapies such as chemotherapy, immunotherapy, radiotherapy and even surgery. Intestinal microbiome has been shown to participate in the resistance to a wide range of anticancer treatments by direct interaction with the treatment or by indirectly stimulating host response through immunomodulation. Interestingly, these effects were described on colorectal cancer but also in other types of malignancies. In addition to their role in therapy efficacy, gut microbiota could also impact side effects induced by anticancer treatments. In the first part of this review, we summarized the role of the gut microbiome on the efficacy and side effects of various anticancer treatments and underlying mechanisms. In the second part, we described the new microbiota-targeting strategies, such as probiotics and prebiotics, antibiotics, fecal microbiota transplantation and physical activity, which could be effective adjuvant therapies developed in order to improve anticancer therapeutic efficiency.

APA, Harvard, Vancouver, ISO, and other styles

24

Bai, Yun, Gerile Aodeng, Lu Ga, Wenfeng Hai, and Jun Ai. "Research Progress of Metal Anticancer Drugs." Pharmaceutics 15, no. 12 (December 11, 2023): 2750. http://dx.doi.org/10.3390/pharmaceutics15122750.

Full text

Abstract:

Cancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are the inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent of the 50 percent of cancer patients who are able to receive conventional chemotherapy survive. Because of these factors, being able to develop a drug and treatment that can target only cancer cells without affecting normal cells remains a big challenge. Since the special properties of cisplatin in the treatment of malignant tumors were accidentally discovered in the last century, metal anticancer drugs have become a research hotspot. Metal anticancer drugs have unique pharmaceutical properties, such as ruthenium metal drugs with their high selectivity, low toxicity, easy absorption by tumor tissue, excretion, and so on. In recent years, efficient and low-toxicity metal antitumor complexes have been synthesized. In this paper, the scientific literature on platinum (Pt), ruthenium (Ru), iridium (Ir), gold (Au), and other anticancer complexes was reviewed by referring to a large amount of relevant literature at home and abroad.

APA, Harvard, Vancouver, ISO, and other styles

25

Tiyanont, Tanin, Nintita Sripaibookij Thokanit, Vijj Kasemsup, Ekaphop Sirachainan, Siriporn Semsarn, and Phichai Chansriwong. "The role of integrating palliative care with systemic anticancer treatment at end-of-life: A single center experience." Journal of Clinical Oncology 42, no. 16_suppl (June 1, 2024): e24067-e24067. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e24067.

Full text

Abstract:

e24067 Background: This study examines the utilization of systemic anticancer treatments, including chemotherapy, targeted therapy, and immunotherapy, in advanced cancer patients. Specifically, it aims to underscore the impact of integrating palliative care in the administration of anticancer treatment during the last months of life. Methods: A retrospective chart review of patients who received chemotherapy, targeted therapy, and immunotherapy at Ramathibodi Hospital and passed away between January 1, 2019, and December 31, 2022. Demographic data, cancer type, modality, intent, and route of anticancer therapy, as well as health scheme and referral to palliative care services, were collected. Information regarding systemic anticancer treatments administered at 2 weeks, 1 month, 3 months, and 6 months preceding death underwent thorough analysis. Logistic regression was employed to assess odds ratios (OR) and 95% CIs for factors influencing decision-making regarding anticancer treatments. Results: Among the 542 deceased patients, 378 had received anticancer treatments within the last 6 months of life. The distribution of anticancer treatments categorized by timing—6 months, 3 months, 1 month, and 2 weeks before death—was 378 (69.7%), 388 (71.6%), 206 (38.0%), and 129 (23.8%), respectively. Older adults constituted nearly half of the population (45.2%). The utilization of anticancer treatments, particularly in the realms of targeted therapy and immunotherapy, at the terminal stages of life is showing a discernible upward trend. Palliative care consultations were present in 26.9% of cases during cancer care. The presence of palliative care consultation was significantly associated with lower odds ratios of receiving end-of-life anticancer treatments at 2 weeks and 1 month before death (OR: 0.55 [95% CI: 0.33 to 0.89], p = 0.016 and 0.54 [95% CI: 0.36 to 0.85], p = 0.004, respectively). Specifically, integrating palliative care reduced the use of chemotherapy in treatment at 2 weeks and 1 month before death (OR: 0.51 [95% CI: 0.27 to 0.98], p = 0.042 and OR: 0.55 [95% CI: 0.33 to 0.90], p = 0.019, respectively). However, the data showed a decrease in the number of patients; nonetheless, no statistically significant differences were observed in the utilization of targeted therapy and immunotherapy. In our analysis, we examine the factors influencing the utilization of anticancer treatments, reveal that there were no significant differences observed among other factors, including age, cancer type, and health scheme. Conclusions: Integration of palliative care into oncology services significantly correlated with a reduced risk of receiving anticancer treatments, particularly chemotherapy, within the last 30 days of life for advanced cancer patients. Insufficient evidence exists to ascertain the impact of palliative care on the utilization of targeted therapy and immunotherapy.

APA, Harvard, Vancouver, ISO, and other styles

26

Alven, Sibusiso, and Blessing Atim Aderibigbe. "The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment." Pharmaceutics 12, no. 12 (December 15, 2020): 1212. http://dx.doi.org/10.3390/pharmaceutics12121212.

Full text

Abstract:

Breast cancer is among the most common types of cancer in women and it is the cause of a high rate of mortality globally. The use of anticancer drugs is the standard treatment approach used for this type of cancer. However, most of these drugs are limited by multi-drug resistance, drug toxicity, poor drug bioavailability, low water solubility, poor pharmacokinetics, etc. To overcome multi-drug resistance, combinations of two or more anticancer drugs are used. However, the combination of two or more anticancer drugs produce toxic side effects. Micelles and dendrimers are promising drug delivery systems that can overcome the limitations associated with the currently used anticancer drugs. They have the capability to overcome drug resistance, reduce drug toxicity, improve the drug solubility and bioavailability. Different classes of anticancer drugs have been loaded into micelles and dendrimers, resulting in targeted drug delivery, sustained drug release mechanism, increased cellular uptake, reduced toxic side effects of the loaded drugs with enhanced anticancer activity in vitro and in vivo. This review article reports the biological outcomes of dendrimers and micelles loaded with different known anticancer agents on breast cancer in vitro and in vivo.

APA, Harvard, Vancouver, ISO, and other styles

27

Park, Hye-Jin. "Current Uses of Mushrooms in Cancer Treatment and Their Anticancer Mechanisms." International Journal of Molecular Sciences 23, no. 18 (September 10, 2022): 10502. http://dx.doi.org/10.3390/ijms231810502.

Full text

Abstract:

Cancer is the leading cause of mortality worldwide. Various chemotherapeutic drugs have been extensively used for cancer treatment. However, current anticancer drugs cause severe side effects and induce resistance. Therefore, the development of novel and effective anticancer agents with minimal or no side effects is important. Notably, natural compounds have been highlighted as anticancer drugs. Among them, many researchers have focused on mushrooms that have biological activities, including antitumor activity. The aim of this review is to discuss the anticancer potential of different mushrooms and the underlying molecular mechanisms. We provide information regarding the current clinical status and possible modes of molecular actions of various mushrooms and mushroom-derived compounds. This review will help researchers and clinicians in designing evidence-based preclinical and clinical studies to test the anticancer potential of mushrooms and their active compounds in different types of cancers.

APA, Harvard, Vancouver, ISO, and other styles

28

Braish, Julie, Lisa Holle, Victoria Forbes, Garima Gautam, and Agnes McAuliffe. "Hepatitis B serology testing in patients with cancer initiating anticancer therapy." JCO Oncology Practice 19, no. 11_suppl (November 2023): 375. http://dx.doi.org/10.1200/op.2023.19.11_suppl.375.

Full text

Abstract:

375 Background: The prevalence of hepatitis B virus (HBV) in the US is ~5%. Patients receiving anticancer therapy with a history of HBV infection are at risk for viral reactivation leading to hepatitis flare, liver failure, and death. The American Society of Clinical Oncology (ASCO) updated 2020 HBV screening and management guidelines recommending all patients have HBV serologies before anticancer therapy initiation. In August 2021, only 17% of patients initiating anticancer therapy at UConn Health had HBV serology screening before treatment. We aimed to increase the HBV screening rate by at least 50%, using HBV serologies before initiation of anticancer therapy. Methods: The plan-do-study-act method was used to conduct this quality improvement (QI) project. To increase the HBV screening rate, we provided education and a two-part HBV serology ordering process improvement. Education consisted of an e-mail to cancer center providers and nurses detailing updated ASCO HBV screening and recommendations. The ordering process improvement plan included 1) multidisciplinary team created HBV serology order, which could be ordered inside or outside of anticancer treatment plan and 2) best practice advisory (BPA) alert to providers when a new anticancer treatment plan was opened. Part 2 of the ordering process improvement plan included incorporation of HBV serology order set directly into anticancer treatment plans along with other baseline laboratory orders to reduce provider time and eliminate the need for BPA. A two-part retrospective chart review was conducted, using an electronic medical record report of patients initiating anticancer treatment plans between treatment periods (pre -intervention and post-intervention). Inclusion criteria included: patients > 18 years and treated with anticancer therapy for newly diagnosed cancer. Patients were excluded if they had known or suspected HBV infection; or were within the Department of Corrections. Results: During the post-implementation phase, 125 patients initiated a new anticancer treatment plan. Of these, 30 (24%) patients were excluded: 18 received prior treatment before HBV serology implementation, 6 received previous anticancer treatment, 5 did not receive anticancer treatment, and 1 was a Department of Correction patient. Out of 95 remaining eligible patients, 84 patients (88.5%) had HBV serologies performed before treatment initiation. Conclusions: Incorporating HBV serologies into anticancer treatment plans appears to be a reliable, acceptable, and valid means to increase adherence to ASCO guidelines related to HBV screening prior to initiation of anticancer therapy. We plan to initiate a follow-up analysis to identify reasons why HBV serologies were not obtained in 12% of patients to inform further QI interventions, and to ensure appropriate management of patients with positive HBV serology results.

APA, Harvard, Vancouver, ISO, and other styles

29

Maiuolo, Jessica, Micaela Gliozzi, Cristina Carresi, Vincenzo Musolino, Francesca Oppedisano, Federica Scarano, Saverio Nucera, et al. "Nutraceuticals and Cancer: Potential for Natural Polyphenols." Nutrients 13, no. 11 (October 27, 2021): 3834. http://dx.doi.org/10.3390/nu13113834.

Full text

Abstract:

Cancer is one of the leading causes of death globally, associated with multifactorial pathophysiological components. In particular, genetic mutations, infection or inflammation, unhealthy eating habits, exposition to radiation, work stress, and/or intake of toxins have been found to contribute to the development and progression of cancer disease states. Early detection of cancer and proper treatment have been found to enhance the chances of survival and healing, but the side effects of anticancer drugs still produce detrimental responses that counteract the benefits of treatment in terms of hospitalization and survival. Recently, several natural bioactive compounds were found to possess anticancer properties, capable of killing transformed or cancerous cells without being toxic to their normal counterparts. This effect occurs when natural products are associated with conventional treatments, thereby suggesting that nutraceutical supplementation may contribute to successful anticancer therapy. This review aims to discuss the current literature on four natural bioactive extracts mostly characterized by a specific polyphenolic profile. In particular, several activities have been reported to contribute to nutraceutical support in anticancer treatment: (1) inhibition of cell proliferation, (2) antioxidant activity, and (3) anti-inflammatory activity. On the other hand, owing to their attenuation of the toxic effect of current anticancer therapies, natural antioxidants may contribute to improving the compliance of patients undergoing anticancer treatment. Thus, nutraceutical supplementation, along with current anticancer drug treatment, may be considered for better responses and compliance in patients with cancer. It should be noted, however, that when data from studies with bioactive plant preparations are discussed, it is appropriate to ensure that experiments have been conducted in accordance with accepted pharmacological research practices so as not to disclose information that is only partially correct.

APA, Harvard, Vancouver, ISO, and other styles

30

Germain, Nicolas, Mélanie Dhayer, Marie Boileau, Quentin Fovez, Jerome Kluza, and Philippe Marchetti. "Lipid Metabolism and Resistance to Anticancer Treatment." Biology 9, no. 12 (December 16, 2020): 474. http://dx.doi.org/10.3390/biology9120474.

Full text

Abstract:

Metabolic reprogramming is crucial to respond to cancer cell requirements during tumor development. In the last decade, metabolic alterations have been shown to modulate cancer cells’ sensitivity to chemotherapeutic agents including conventional and targeted therapies. Recently, it became apparent that changes in lipid metabolism represent important mediators of resistance to anticancer agents. In this review, we highlight changes in lipid metabolism associated with therapy resistance, their significance and how dysregulated lipid metabolism could be exploited to overcome anticancer drug resistance.

APA, Harvard, Vancouver, ISO, and other styles

31

Vazquez, Alexei. "Optimization of personalized therapies for anticancer treatment." BMC Systems Biology 7, no. 1 (2013): 31. http://dx.doi.org/10.1186/1752-0509-7-31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Raucher, Drazen, and Jung Su Ryu. "Cell-penetrating peptides: strategies for anticancer treatment." Trends in Molecular Medicine 21, no. 9 (September 2015): 560–70. http://dx.doi.org/10.1016/j.molmed.2015.06.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Debatin, Klaus-Michael. "Activation of apoptosis pathways by anticancer treatment." Toxicology Letters 112-113 (March 2000): 41–48. http://dx.doi.org/10.1016/s0378-4274(99)00252-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Sequeira, C. A. C., and D. S. P. Cardoso. "Electrotherapy, a recent mode for anticancer treatment." Ciência & Tecnologia dos Materiais 26, no. 2 (July 2014): 126–30. http://dx.doi.org/10.1016/j.ctmat.2015.03.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

van Alphen, R. J., E. A. C. Wiemer, H. Burger, and F. A. L. M. Eskens. "The spliceosome as target for anticancer treatment." British Journal of Cancer 100, no. 2 (November 25, 2008): 228–32. http://dx.doi.org/10.1038/sj.bjc.6604801.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Stathis, Anastasios, and Francesco Bertoni. "BET Proteins as Targets for Anticancer Treatment." Cancer Discovery 8, no. 1 (December 20, 2017): 24–36. http://dx.doi.org/10.1158/2159-8290.cd-17-0605.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Pranchevicius, Maria-Cristina S., and Thiessa R. Vieira. "Production of recombinant immunotherapeutics for anticancer treatment." Bioengineered 4, no. 5 (September 2013): 305–12. http://dx.doi.org/10.4161/bioe.24666.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Fernández, Ariel. "Synergizing immunotherapy with molecular-targeted anticancer treatment." Drug Discovery Today 19, no. 9 (September 2014): 1427–32. http://dx.doi.org/10.1016/j.drudis.2014.03.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Fumagalli, Gaia, Cristina Marucci, Michael S. Christodoulou, Barbara Stella, Franco Dosio, and Daniele Passarella. "Self-assembly drug conjugates for anticancer treatment." Drug Discovery Today 21, no. 8 (August 2016): 1321–29. http://dx.doi.org/10.1016/j.drudis.2016.06.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Zhang, Jing-Jing, Wei Lu, Raymond Wai-Yin Sun, and Chi-Ming Che. "Organogold(III) Supramolecular Polymers for Anticancer Treatment." Angewandte Chemie International Edition 51, no. 20 (April 4, 2012): 4882–86. http://dx.doi.org/10.1002/anie.201108466.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Zhang, Jing-Jing, Wei Lu, Raymond Wai-Yin Sun, and Chi-Ming Che. "Organogold(III) Supramolecular Polymers for Anticancer Treatment." Angewandte Chemie 124, no. 20 (April 3, 2012): 4966–70. http://dx.doi.org/10.1002/ange.201108466.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Elekofehinti, Olusola Olalekan, Opeyemi Iwaloye, Femi Olawale, and Esther Opeyemi Ariyo. "Saponins in Cancer Treatment: Current Progress and Future Prospects." Pathophysiology 28, no. 2 (June 5, 2021): 250–72. http://dx.doi.org/10.3390/pathophysiology28020017.

Full text

Abstract:

Saponins are steroidal or triterpenoid glycoside that is distinguished by the soap-forming nature. Different saponins have been characterized and purified and are gaining attention in cancer chemotherapy. Saponins possess high structural diversity, which is linked to the anticancer activities. Several studies have reported the role of saponins in cancer and the mechanism of actions, including cell-cycle arrest, antioxidant activity, cellular invasion inhibition, induction of apoptosis and autophagy. Despite the extensive research and significant anticancer effects of saponins, there are currently no known FDA-approved saponin-based anticancer drugs. This can be attributed to a number of limitations, including toxicities and drug-likeness properties. Recent studies have explored options such as combination therapy and drug delivery systems to ensure increased efficacy and decreased toxicity in saponin. This review discusses the current knowledge on different saponins, their anticancer activity and mechanisms of action, as well as promising research within the last two decades and recommendations for future studies.

APA, Harvard, Vancouver, ISO, and other styles

43

Wargasetia, Teresa Liliana, Hana Ratnawati, and Nashi Widodo. "Sea Cucumber Compounds Targeting NF-κB in Cancer Treatment." Bioinformatics and Biology Insights 16 (January 2022): 117793222210917. http://dx.doi.org/10.1177/11779322221091740.

Full text

Abstract:

Cancer is a major health problem worldwide and the leading cause of death in many countries. It remains challenging to find anticancer treatments that work efficiently for varying types of cancer cells. Several studies revealed that nuclear factor kappa B (NF-κB) is a family of dimeric transcription factors that induce tumor promotion, progression, and therapeutic resistance, providing evidence that NF-kB may be a promising target for cancer drugs. Some research has found that sea cucumber biocompounds have anticancer properties, but further research is essential to confirm anticancer targets. This manuscript discusses the mechanisms of anticancer targeting the NF-κB signaling pathway induced by sea cucumber-derived compounds. Additional database analysis showed the protein targeted by the compounds involved in several pathways related to the NF-κB network. Moreover, SwissADME predicted druglikeliness properties of the active compounds of sea cucumber. The discussion is expected to provide new insight into the promising potential of these marine natural products for the treatment of many different types of cancers.

APA, Harvard, Vancouver, ISO, and other styles

44

Ghaffari, Tayyebeh, Joo-Hyun Hong, Solmaz Asnaashari, Safar Farajnia, Abbas Delazar, Hamed Hamishehkar, and Ki-Hyun Kim. "Natural Phytochemicals Derived from Gymnosperms in the Prevention and Treatment of Cancers." International Journal of Molecular Sciences 22, no. 12 (June 21, 2021): 6636. http://dx.doi.org/10.3390/ijms22126636.

Full text

Abstract:

The incidence of various types of cancer is increasing globally. To reduce the critical side effects of cancer chemotherapy, naturally derived compounds have been considered for cancer treatment. Gymnosperms are a group of plants found worldwide that have traditionally been used for therapeutic applications. Paclitaxel is a commercially available anticancer drug derived from gymnosperms. Other natural compounds with anticancer activities, such as pinostrobin and pinocembrin, are extracted from pine heartwood, and pycnogenol and enzogenol from pine bark. Gymnosperms have great potential for further study for the discovery of new anticancer compounds. This review aims to provide a rational understanding and the latest developments in potential anticancer compounds derived from gymnosperms.

APA, Harvard, Vancouver, ISO, and other styles

45

Taper, H. S., and M. B. Roberfroid. "Inulin/oligofructose and anticancer therapy." British Journal of Nutrition 87, S2 (May 2002): S283—S286. http://dx.doi.org/10.1079/bjn/2002549.

Full text

Abstract:

The results of our investigations indicate that dietary treatment with inulin or oligofructose incorporated in the basal diet for experimental animals: (i) reduced the incidence of mammary tumors induced in Sprague-Dawley rats by methylnitrosourea; (ii) inhibited the growth of transplantable malignant tumors in mice; and (iii) decreased the incidence of lung metastases of a malignant tumor implanted intramuscularily in mice. Moreover, besides such cancer risk reduction effects, the dietary treatment with inulin or oligofructose significantly potentiated the effects of subtherapeutic doses of six different cytotoxic drugs commonly utilized in human cancer treatment. If confirmed, such dietary treatment with inulin or oligofructose potentiating cancer therapy might become an interesting approach to complement classical protocols of human cancer treatment without any additional risk for the patients.

APA, Harvard, Vancouver, ISO, and other styles

46

Lee, Jun H., and Anjan Nan. "Combination Drug Delivery Approaches in Metastatic Breast Cancer." Journal of Drug Delivery 2012 (April 26, 2012): 1–17. http://dx.doi.org/10.1155/2012/915375.

Full text

Abstract:

Disseminated metastatic breast cancer needs aggressive treatment due to its reduced response to anticancer treatment and hence low survival and quality of life. Although in theory a combination drug therapy has advantages over single-agent therapy, no appreciable survival enhancement is generally reported whereas increased toxicity is frequently seen in combination treatment especially in chemotherapy. Currently used combination treatments in metastatic breast cancer will be discussed with their challenges leading to the introduction of novel combination anticancer drug delivery systems that aim to overcome these challenges. Widely studied drug delivery systems such as liposomes, dendrimers, polymeric nanoparticles, and water-soluble polymers can concurrently carry multiple anticancer drugs in one platform. These carriers can provide improved target specificity achieved by passive and/or active targeting mechanisms.

APA, Harvard, Vancouver, ISO, and other styles

47

Crintea, Andreea, Alexandru Cătălin Motofelea, Alina Simona Șovrea, Anne-Marie Constantin, Carmen-Bianca Crivii, Rahela Carpa, and Alina Gabriela Duțu. "Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment—An Overview." Pharmaceutics 15, no. 5 (May 4, 2023): 1406. http://dx.doi.org/10.3390/pharmaceutics15051406.

Full text

Abstract:

Cancer is a leading cause of death worldwide, and the main treatment methods for this condition are surgery, chemotherapy, and radiotherapy. These treatment methods are invasive and can cause severe adverse reactions among organisms, so nanomaterials are increasingly used as structures for anticancer therapies. Dendrimers are a type of nanomaterial with unique properties, and their production can be controlled to obtain compounds with the desired characteristics. These polymeric molecules are used in cancer diagnosis and treatment through the targeted distribution of some pharmacological substances. Dendrimers have the ability to fulfill several objectives in anticancer therapy simultaneously, such as targeting tumor cells so that healthy tissue is not affected, controlling the release of anticancer agents in the tumor microenvironment, and combining anticancer strategies based on the administration of anticancer molecules to potentiate their effect through photothermal therapy or photodynamic therapy. The purpose of this review is to summarize and highlight the possible uses of dendrimers regarding the diagnosis and treatment of oncological conditions.

APA, Harvard, Vancouver, ISO, and other styles

48

Torić, Jelena, Ana Karković Marković, Cvijeta Jakobušić Brala, and Monika Barbarić. "Anticancer effects of olive oil polyphenols and their combinations with anticancer drugs." Acta Pharmaceutica 69, no. 4 (December 1, 2019): 461–82. http://dx.doi.org/10.2478/acph-2019-0052.

Full text

Abstract:

Abstract Cancer presents one of the leading causes of death in the world. Current treatment includes the administration of one or more anticancer drugs, commonly known as chemotherapy. The biggest issue concerning the chemotherapeutics is their toxicity on normal cells and persisting side effects. One approach to the issue is chemoprevention and the other one is the discovery of more effective drugs or drug combinations, including combinations with polyphenols. Olive oil polyphenols (OOPs), especially hydroxytyrosol (HTyr), tyrosol (Tyr) and their derivatives oleuropein (Ole), oleacein and oleocanthal (Oc) express anticancer activity on different cancer models. Recent studies report that phenolic extract of virgin olive oil may be more effective than the individual phenolic compounds. Also, there is a growing body of evidence about the combined treatment of OOPs with various anticancer drugs, such as cisplatin, tamoxifen, doxorubicin and others. These novel approaches may present an advanced strategy in the prevention and treatment of cancer.

APA, Harvard, Vancouver, ISO, and other styles

49

Gattellari, Melina, Katie J. Voigt, Phyllis N. Butow, and Martin H. N. Tattersall. "When the Treatment Goal Is Not Cure: Are Cancer Patients Equipped to Make Informed Decisions?" Journal of Clinical Oncology 20, no. 2 (January 15, 2002): 503–13. http://dx.doi.org/10.1200/jco.2002.20.2.503.

Full text

Abstract:

PURPOSE: Informed decision making now is considered the underpinning of ethical medical practice. We aimed to determine the extent to which patients with incurable cancer are adequately informed of their prognosis and treatment options and encouraged to participate in treatment decisions. PATIENTS AND METHODS: One hundred eighteen cancer patients with incurable disease presenting for an initial consultation with one of nine oncologists at two Sydney tertiary referral hospitals participated in the study. Consultations were recorded on audiotape to permit a content analysis of doctor-patient interactions. We devised a coding system to assess disclosure of information and to evaluate doctor encouragement of patient participation in treatment decision making. Patient recall, satisfaction, anxiety, and perceptions of the decision-making process were assessed to determine the effects of informed decision making on patient outcomes. RESULTS: Most patients were informed about the aim of anticancer treatment (84.7%), that their disease was incurable (74.6%), and about life expectancy (57.6%). An alternative to anticancer treatments was presented to 44.1%, 36.4% were informed about how anticancer treatment would affect quality of life, and 29.7% were offered a management choice. Oncologists checked patient understanding in only 10.2% of consultations. Although greater information disclosure did not seem to elevate anxiety levels, greater patient participation in the decision-making process was associated with increased anxiety levels (P = .0005), which persisted over a 2-week time span. CONCLUSION: Most patients were well informed, but important gaps remain, especially concerning information about prognosis and alternatives to anticancer treatment. These gaps invite the question concerning whether patients are led toward anticancer treatment.

APA, Harvard, Vancouver, ISO, and other styles

50

Calvo, Anne Sophie, Juliette Rochefort, Marie José Javelot, Vianney Descroix, and Géraldine Lescaille. "Management of mTOR inhibitors oral mucositis: current state of knowledge." Journal of Oral Medicine and Oral Surgery 25, no. 1 (2019): 11. http://dx.doi.org/10.1051/mbcb/2018027.

Full text

Abstract:

Introduction: Mucositis is a well-known side effect of classic anticancer treatments (chemotherapy and radiotherapy). Thanks to the major developments in personalizing treatments through the development of targeted treatment, various specific intraoral lesions have been described. Purpose: mTOR inhibitors are targeted anticancer treatments that are used to treat various cancer types. They can cause intraoral ulcerations that can be serious, and that can lead to a dose reduction or the anticancer treatment being stopped altogether. The management of these disabling and painful lesions is a major part of ensuring the efficiency of the cancer treatments. The objective of this article is to evaluate the current knowledge about the different treatments used nowadays, especially the preventive treatments. Conclusion: An efficient management of the lesions is a major part of the management of patients treated with mTOR inhibitors and should be carried out by the oral cavity specialists.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!